Scientists Found a "Window" to Stop Brain Metastasis Early

Metastasis — the spread of cancer beyond its original tumor — causes the majority of cancer deaths, and lesions that reach the brain are among the most feared. Now a team led by Manuel Valiente at the Spanish National Cancer Research Centre in Madrid has uncovered something no one had seen before: a brief, vulnerable pause that spreading cancer cells take as they colonize the brain, along with a way to kill them during it. In a study published September 29, the researchers show that three drugs eliminated the microscopic seeds of brain metastasis in mice and in samples of human tissue before those seeds could grow into detectable tumors.

The project took more than six years and brought together over seventy co-authors from roughly twenty institutions across Spain, the United Kingdom, Germany, France and the United States, according to the research centre. Crucially, the team validated the finding not only in animal models but in human brain metastasis samples taken from autopsies and surgeries, including fresh tissue from the Spanish RENACER brain metastasis network — the first molecular profile of human micrometastases actively colonizing the brain.

What happens inside the "proliferative pause"

Cancer cells that survive the journey to the brain do not start dividing right away. The researchers found that they enter a transient "proliferative pause" — temporarily switching off multiplication through a protein called MXD4, which counters the growth-driver MYC — while they adapt to the brain's hostile environment. During this adaptation, the cells lean on specific stress-buffering programs: they cling to blood vessels, ramp up their DNA-damage repair machinery and carefully manage their protein production. Those dependencies are the vulnerability the team exploited — block the survival programs, and the micrometastases die before they can resume growing.

Lead author Pedro García-Gómez said the group analyzed the biology of micrometastases that are still clinically undetectable, and because drugs already existed whose targets matched the active molecules, the team tested three of them in animal models — where they eliminated the hidden seeds before detectable metastases could develop. The authors describe the finding as a previously unknown adaptive stage of metastatic colonization with exploitable weaknesses.

The drugs that cleared the hidden brain metastasis seeds

Each drug targeted a different survival program the paused cells depend on. The most striking was venetoclax, sold as Venclexta and already approved for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia: in a small-cell lung cancer mouse model it reduced the brain metastatic burden, and in human tissue cultures it likewise destroyed micrometastases. Two investigational agents completed the picture — ceralasertib, which inhibits the DNA-damage-response protein ATR, and the brain-penetrating compound obatoclax, which targets the BCL-2 survival pathway. In mice, obatoclax cut the burden of full-blown metastases, extended survival and reduced relapse after simulated neurosurgery.

All three agents were also tested in patient-derived organotypic cultures — living slices of human brain metastasis tissue — where they reduced the population of metastasis-initiating cells clinging to blood vessels. The result held across spontaneous mouse models, post-surgical relapse models and human samples, which is why the team believes the vulnerability may apply to metastasis in other organs too.

Why it matters: prevention instead of treatment

Treating visible metastases has always been oncology's uphill battle: by the time a brain lesion shows up on a scan, options narrow quickly and the prognosis darkens. Striking the seeds during their quiet adaptation phase flips the strategy from treatment to prevention — and points toward a future in which drug regimens given after cancer surgery could stop brain metastasis from returning. The same vulnerability signature even showed up at the invasive front of established metastases, suggesting the most realistic near-term application is guarding against recurrence after a tumor has been removed.

The long road from the lab to the clinic

None of this is a therapy yet, and the caveats are significant. There are currently no diagnostic tests capable of detecting micrometastases in a living patient, and no biomarkers that reliably flag who is at risk — so doctors could not yet know whom to treat. Valiente acknowledges the gap: the discovery "opens a window of opportunity to attack the disease before symptoms appear," but his group is now racing to find the biomarkers that would make that window usable in practice.

The evidence is also preclinical, and the paper itself cautions that giving preventive drugs from the moment of a cancer diagnosis onward would be "clinically challenging," with adaptive escape a real possibility. The team's medium-term plan is clinical trials focused first on the post-surgery window, where relapse currently has no clear therapeutic strategy. As Valiente puts it, "this is the beginning of the race to prevent metastasis" — not the finish line. For now, the study stands as the first proof that metastatic colonization has an attackable phase at all; full details appear in the CNIO's announcement of the work and coverage by News-Medical. See also our health coverage, including a recent WHO study finding that one in eight cancers is linked to infection.